Study wrapper · #538
Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.
Editor's note
This analysis pools two phase III randomized (2:1) placebo-controlled trials (806 participants) to identify who is most likely to respond to tesamorelin for excess abdominal fat in people with HIV. Researchers reported that metabolic syndrome (NCEP-defined), elevated triglycerides, and white race were each associated with a higher likelihood of visceral-fat response at 6 months, that no predictors emerged at 3 months, and that the odds of reaching a lower-risk visceral-fat threshold (<140 cm2) were about 3.9 times greater with tesamorelin than placebo after adjustment. The large phase III base is a strength; this is a secondary predictor analysis using surrogate fat thresholds rather than clinical outcomes. It supports tesamorelin's established visceral-fat effect and adds practical detail on which patients tend to respond.
Plain-language abstract
Not everyone responds equally to tesamorelin, so researchers pooled two large trials (806 people with HIV and excess belly fat) to see who benefits most. Participants received tesamorelin or placebo by daily injection for six months. People who had metabolic syndrome, higher triglycerides, or were white were more likely to show a meaningful reduction in deep belly fat at six months; no useful predictors showed up at three months. Overall, those on tesamorelin were nearly four times as likely as those on placebo to reach a belly-fat level linked to lower health risk, after accounting for sex, body-mass index, and starting fat amount. The study used data from rigorous trials but looked back at who responded rather than testing a new question, and it measured a fat-level target rather than long-term health outcomes. It helps identify which patients tend to respond to tesamorelin.